2024 CEI Annual SurveyPlease complete the 2024 CEI Annual Survey.

Logo

Course

Non-Alcoholic Fatty Liver Disease (NAFLD) in Persons Living with HIV

Details

Published Date: 03/31/2022

Expiration Date: 02/16/2025

CE Credit: CME:1CNE: 1(Rx: 0.25)

Description

This course will ensure that clinicians know the prevalence and risk factors for Non-Alcoholic Fatty Liver Disease NAFLD and Non-Alcoholic Steatohepatitis (NASH) in PLWH, the screening protocols and riskof progression of NASH-related liver fibrosis in PLWH, lessons learned from NASH clinical trials in non-HIV patients and the therapeutic landscape for NASH in PLWH.

Presenter(s)

Meena Bansal ,MD

Meena Bansal, MD is tenured Professor of Medicine and NIH funded investigator with a long-standing interest in studying molecular mechanisms of liver fibrosis in Persons Living with HIV (PWH) as well as those without HIV. She has served as the Principal Investigator for numerous clinical trials for NASH, has developed a screening protocol and database for HIV patients with NAFLD/NASH, and is now launching and leading the NASH Center of Excellence at Mount Sinai. The Center will focus on patient identification, care standardization, risk stratification including predictive algorithms, and translational and clinical research. 

Learning Objectives

  • Discuss the prevalence and risk factors for Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) in Persons Living with HIV (PLWH).
  • Explain screening protocols and risk of progression of NASH-related liver fibrosis in PLWH.
  • List the lessons learned from NASH clinical trials in non-HIV patients.
  • Describe the therapeutic landscape for NASH in PLWH.

Continuing Education Credit Information